✦ LIBER ✦

PUK5 COST-BENEFITS ANALYSIS OF DIET VERSUS DIALYSIS IN ELDERLY CKD5 PATIENTS

✍ Scribed by F Borghetti; L Scalone; B Brancati; L Sottini; G Brunori; BF Viola; G Cancarini; LG Mantovani

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

PUK25 USING GENETIC POLYMORPHISM AS A ST

✍ Vegter, S; Muntinghe, FL; Verduijn, M; Boeschoten, EW; Dekker, FW; Navis, G; Pos 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 97 KB

Cost-benefit analysis of capecitabine ve

✍ Frank G.A Jansman; Maarten J Postma; David van Hartskamp; Pax H.B Willemse; Jaco 📂 Article 📅 2004 🏛 Elsevier Science 🌐 English ⚖ 106 KB

PCN10 COST ANALYSIS OF CAPECITABINE VERS

✍ MJ Postma; D van Hartskamp; FG Jansman; PH Willemse; JR Brouwers 📂 Article 📅 2002 🏛 John Wiley and Sons 🌐 English ⚖ 66 KB

PSY5 COST-EFFECTIVENESS OF DEFERASIROX V

✍ Lee, KK; Chow, DP; Lau, H; Pramanik, A; Delea, TE; Sofrygin, O; Shi, W 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 69 KB

PCN96 Cost Minimization Analysis of Xelo

✍ K.R. Zhou; A. Cheng; T.Y. Kwok; R. Yao; E. Yip; V.W. Lee 📂 Article 📅 2012 🏛 John Wiley and Sons 🌐 English ⚖ 60 KB

PUK11 A COST-UTILITY ANALYSIS OF SOLIFEN

✍ L Cardozo; A Thorpe; M Grishchenko; MK Sidhu 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 69 KB